Loading patent…
AssigneesInstitut National de la Sante et de la Recherche Medicale, Assistance Publique-Hopitaux de Paris, Baylor Research Institute, Universite Paris Est Creteil Val De Marne
InventorsYves LEVY, Gérard ZURAWSKI, Sandra ZURAWSKI, Mireille CENTLIVRE, Christine LACABARATZ, Sylvain CARDINAUD, Mathieu SURENAUD
Estimating the term…
Sarbecoviruses (lineage B of genus Betacoronavirus) have caused two major outbreaks during the past two decades: SARS-CoV in 2003, and SARS-CoV-2 from 2019. SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. Therefore, universal vaccines against this class of viruses are key to ending the current pandemic, but also for preventing additional emergent variations and future outbreaks of SARS-like viruses that are continuously found from nature reservoirs. Now, the inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain is conjugated or fused to a protein N polypeptide of SAR-CoV-2 and the light chain is fused to a RBD polypeptide. In particular, the inventors show that said antibody could elicit immune responses against Sarbecoviruses.
-18. (canceled)
An antibody comprising a heavy chain and a light chain, wherein the antibody is directed against a surface antigen of an antigen presenting cell and wherein:
Dependencies are inferred from the claim text.